At first glance, it does not seem to make a difference whether or not patients with a specific cardiac arrhythmia, atrial fibrillation, who had an intracerebral haemorrhage while they used anticoagulants, restart anticoagulants or not. With either option, the risk of stroke or death due to a vascular cause was similar. This result emerges from research co-led by Radboud university medical center and UMC Utrecht, now published in The Lancet Neurology. The study calls for a large follow-up study to provide insight into whether or not anticoagulation should be given in specific subgroups of these patients.
Patients with atrial fibrillation, a heart rhythm disorder in which the heart beats irregularly and often faster than normal, are often given anticoagulation to ensure that blood does not clot as quickly, thus reducing the risk of ischaemic stroke (caused by a clogged blood vessel). However, anticoagulation increases the risk of a brain haemorrhage, which occurs when a blood vessel in the brain ruptures.
A complicated dilemma, then, for patients and their doctors. “Do we prescribe this anticoagulation again to a patient with this cardiac arrhythmia after a brain haemorrhage, with the risk of another haemorrhage? Or do we not, which then increases the risk of an ischaemic stroke?” explains Professor of Neurology Karin Klijn. In the past, most practitioners tended not to prescribe the medicine again, but there was a lack of good evidence for this. Klijn: “The available scientific studies only looked retrospectively at how patients fared. Doctors had therefore already made a choice as to whether or not to prescribe anticoagulation, based on, for example, age and other characteristics. A study in which patients were randomly allocated to one of the two treatments and that then compared the two groups, was therefore lacking.”
In the absence of scientific evidence, the assumption for a long time has been: let's stop giving these patients anticoagulation. “But perhaps as practitioners we have been too afraid of new brain haemorrhages”, Klijn says. We have hardly found any new treatments to improve outcome after brain haemorrhage in the past 30 years. Intracerebral haemorrhages account for around 15% of all strokes. “We need to increase our knowledge”, Klijn says, “not only about acute treatments but also about secondary prevention, that is, preventing cerebral haemorrhages, cerebral infarctions and other vascular diseases after a haemorrhage in the brain.”
So Radboud university medical center and UMC Utrecht, led by Klijn and her colleague from Utrecht Professor of Neurology Bart van der Worp, started the APACHE-AF study with 14 other centres. In APACHE-AF they studied the effect of prescribing a new anticoagulation (apixaban), or no anticoagulation, in patients with atrial fibrillation who had experienced a haemorrhage in the brain while on anticoagulation. 101 persons participated in this study. The question was: do they develop new health problems, such as another intracerebral haemorrhage, a cerebral infarction or other vascular disease resulting in death?
Initial indications call for follow-up research
The result? No difference was found between the two groups. All study participants were at high annual risk of a new stroke or death due to vascular diseases, regardless of whether they were on anticoagulation or not. The risk for one group did not appear to be greater than for the other. Reason for follow-up. Klijn: “Our goal was to provide initial indications for the level of the risk of new strokes or death from vascular disease in these patients. We succeeded in doing so. Now larger follow-up studies are needed, in which we must zoom in on subgroups. Then we can better determine whether and what role factors like sex, age and other patient-specific characteristics play. That's what we're going to continue with now, together with colleagues from other countries.”
About the publication in The Lancet Neurology
Apixaban versus no anticoagulation after anticoagulation associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial – Floris H B M Schreuder, Koen M van Nieuwenhuizen, […], Berber Zweedijk, Ale Algra, Jan Willem van Dalen, L Jaap Kappelle, Gabriel J E Rinkel, H Bart van der Worp, Catharina J M Klijn.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Yvonne Schoon appointed professor by special appointment 'The right care for the right older person'6 December 2021
Yvonne Schoon has been appointed professor by special appointment 'The right care for the right older person' at the Radboudumc / Radboud University as of 1 October 2021.read more
How much should we exercise to live healthier lives? Research into the relationship between exercise, heart disease and mortality3 December 2021
It has long been known that exercise reduces the risk of many chronic diseases. However, we do not yet know exactly how much exercise is necessary to achieve health benefit.read more
KNAW Early Career Award for Martine Hoogman2 December 2021
Martine Hoogman has been awarded a KNAW Early Career Award. The prize, a sum of 15,000 euros and a work of art, is aimed at researchers in the Netherlands who are at the start of their careers and have innovative, original research ideas.read more
T-Guard can reset immune system1 December 2021
For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard.read more
Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI1 December 2021
Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.read more
Villa Joep Research Grant for Radiotherapy & OncoImmunology (ROI) lab1 December 2021
Renske van den Bijgaart and Gosse Adema from the Radiotherapy & OncoImmunology laboratorium in collaboration with the Prinses Maxima Center received a grant from Villa Joep of 410k Euro.read more